These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 33925695)

  • 1. Next Generation Therapeutics for the Treatment of Myelofibrosis.
    Tremblay D; Mascarenhas J
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel treatments for myelofibrosis: beyond JAK inhibitors.
    Tremblay D; Mesa R
    Int J Hematol; 2022 May; 115(5):645-658. PubMed ID: 35182376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Treatments for Myelofibrosis.
    Tremblay D; Mesa R
    Curr Treat Options Oncol; 2023 Feb; 24(2):61-75. PubMed ID: 36640223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
    Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
    Tremblay D; Hoffman R
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.
    Assi R; Verstovsek S; Daver N
    Curr Opin Hematol; 2017 Mar; 24(2):115-124. PubMed ID: 28072602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.
    Komrokji R; Verstovsek S
    Expert Rev Hematol; 2012 Dec; 5(6):631-41. PubMed ID: 23216593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options.
    Arslan Davulcu E; Oğuz MB; Kılıç E; Eşkazan AE
    Expert Opin Investig Drugs; 2024 Jan; 33(1):27-37. PubMed ID: 38073183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
    Edahiro Y
    Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapies for myelofibrosis.
    Stein BL; Cervantes F; Giles F; Harrison CN; Verstovsek S
    Leuk Lymphoma; 2015; 56(10):2768-78. PubMed ID: 25860240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy of Myelofibrosis.
    Tremblay D; Marcellino B; Mascarenhas J
    Drugs; 2017 Sep; 77(14):1549-1563. PubMed ID: 28791654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of JAK inhibition in myelofibrosis and beyond.
    Mascarenhas JO; Cross NC; Mesa RA
    Blood Rev; 2014 Sep; 28(5):189-96. PubMed ID: 25043171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drug profile: JAK inhibitors.
    Coltoff A; Kuykendall A
    Leuk Lymphoma; 2024 Sep; 65(9):1258-1269. PubMed ID: 38739701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond.
    Harrison CN; McLornan DP
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):489-497. PubMed ID: 29222297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigational non-JAK inhibitors for chronic phase myelofibrosis.
    Bankar A; Gupta V
    Expert Opin Investig Drugs; 2020 May; 29(5):461-474. PubMed ID: 32245330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase signaling and targeted therapy for primary myelofibrosis.
    Yang Q; Crispino JD; Wen QJ
    Exp Hematol; 2017 Apr; 48():32-38. PubMed ID: 28043820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.
    Chifotides HT; Masarova L; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):219-231. PubMed ID: 36797153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.
    Waksal JA; Mascarenhas J
    Curr Hematol Malig Rep; 2022 Oct; 17(5):140-154. PubMed ID: 35984598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.